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Massively parallel sequencing analysis of synchronous
fibroepithelial lesions supports the concept of progression
from fibroadenoma to phyllodes tumor
Salvatore Piscuoglio1,6, Felipe C Geyer1,2,6, Kathleen A Burke1, Melissa P Murray1, Charlotte KY Ng1, Alba Mota1,3, Caterina Marchio4,
Samuel H Berman1, Larry Norton5, Edi Brogi1, Britta Weigelt1 and Jorge S Reis-Filho1
Phyllodes tumors (PTs) and fibroadenomas (FAs) are fibroepithelial lesions (FELs) of the breast. Although mutations affecting exon 2
of MED12 are highly recurrent in FAs and PTs, TERT promoter hotspot mutations are frequently found in PTs but are vanishingly rare
in FAs. Malignant transformation of benign PTs is well-documented, but the progression from FA to PT remains a matter of
contention. Here we report on the somatic genetic alterations in multiple ipsilateral synchronous FELs (three FAs, one benign PT,
and one malignant PT) occurring in the same patient. DNA samples extracted from each tumor and matched normal tissue were
subjected to targeted massively parallel sequencing using the Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable
Cancer Targets (MSK-IMPACT) assay. This analysis revealed MED12 mutations in all lesions. One FA and the benign PT harbored a
MED12Gly44Val mutation, whereas another FA and the malignant PT displayed a MED12Gly44Asp mutation. The remaining FA had an
independent distinct MED12Gly44Cys mutation. A formal clonality analysis suggested a clonal relationship between the FELs with
identical MED12 mutations (Po0.05). A clonal TERT promoter hotspot mutation was identified exclusively in the malignant PT. The
identification of distinct MED12 mutations in multifocal ipsilateral and synchronous FELs supports the notion that co-existing
mammary fibroepithelial tumors can arise independently. Conversely, the co-existence of identical MED12 mutations indicates
clonal relatedness among FAs and PTs, corroborating the hypothesis that FAs may constitute the substrate from which PTs develop.
Our findings also support the notion that acquisition of TERT promoter mutations may drive the progression of FELs.
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INTRODUCTION
Mammary fibroepithelial lesions (FELs) include fibroadenomas
(FAs) and phyllodes tumors (PTs).1 FAs account for the majority of
FELs, have a benign behavior, and are not uncommonly multifocal.
Histologically, FAs are characterized by an admixture of epithelial
and stromal components arranged into pericanalicular and/or
intracanalicular growth patterns.1 By contrast, PTs are relatively
rare neoplasms, accounting for ~ 2.5% of all mammary FELs.1
Histologically, PTs are characterized by an overt intracanalicular
growth pattern and a mesenchymal component with varying
cellularity and atypia, resulting in the formation of leaf-like
projections into epithelium-lined spaces.1 PTs are graded as
benign, borderline, or malignant depending on the stromal
features, including cellularity, nuclear atypia, and proliferation
rate,1 and this grading system correlates, albeit imperfectly, with
their clinical behavior. Although FAs are benign lesions with
limited growth potential, PTs have a tendency for continuous
growth, can recur locally regardless of grade, and metastasize.1
Metastatic events, however, are essentially limited to malignant
PTs or occur after local recurrence with grade progression
following a benign diagnosis.2
FAs and PTs have recently been shown to be underpinned by
highly recurrent hotspot MED12 exon 2 mutations.3–9 These
mutations likely constitute founder events in the development of
most FAs and a subset of PTs, but appear to be neither necessary
nor sufficient to confer the more aggressive behavior character-
istic of PTs.3–10 Recent genomic analyses of FAs and PTs6,9
demonstrated that consistent with the differences in morphologic
appearance and clinical behavior, PTs are genetically more
advanced and display a higher mutational burden than FAs.9 In
addition to MED12 mutations, FAs and PTs were found to harbor
co-occurring RARA mutations.6,9 Although recurrent mutations in
FLNA, SETD2, and KMT2D were found across the spectrum of PTs,
mutations in bona fide cancer genes (e.g., TP53 and RB1) were only
detected in borderline and malignant PTs.6,9 Recurrent clonal
hotspot mutations in the TERT promoter and TERT gene
amplifications have also been documented in FELs.4,6,11 Although
these TERT alterations have been detected in the majority of
borderline and malignant PTs, they have also been detected in a
small subset of benign PTs,4,6,11 and shown to be either specific
for6 or enriched in11 PTs as compared with FAs.
Although there is evidence that benign and borderline PTs can
progress to malignant PTs,12 the progression from FAs to PTs
remains controversial, despite the not uncommon finding of
histologically FA-like areas in PTs and the existence of molecular
evidence based on the loss of heterozygosity and human
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androgen receptor assays, suggesting that some PTs may arise
from FAs.13,14 Interestingly, the frequency of MED12 mutations
appears to diminish with increasing PT grade,4–6 whereas the
frequency of the TERT − 124C4T promoter hotspot mutation and/
or TERT gene amplification has been shown to increase according
to the histologic grade of PTs, with significantly lower rates in
benign (18%) than in borderline (57%) and malignant PTs (68%).6
On the basis of these observations, we have posited that genetic
alterations affecting TERT rather than MED12 mutations may have
a role in the progression of PTs.6
Given that the clonal relatedness analyses between FAs and PTs
carried out to date may not be entirely conclusive, we have
employed targeted massively parallel sequencing (MPS) to
investigate the repertoire of somatic genetic alterations and the
clonal relatedness of multifocal ipsilateral FELs in the breast of a
female patient.
RESULTS
A 37-year-old female patient was diagnosed with five synchronous
and ipsilateral FELs in the right breast. A detailed description of
the clinical history and gross analysis of mastectomy specimen is
provided in the Supplementary Material and Supplementary
Figure 1. After consensus histologic review by four pathologists
with an interest in breast pathology (FCG, MPM, EB, and JSR-F), the
lesions were classified as FAs (n= 3), benign PT (n= 1), and
malignant PT (n= 1) according to World Health Organization
classification1 (Figure 1; Supplementary Table 1).
Representative formalin-fixed paraffin-embedded sections were
microdissected, and DNA of each of the five lesions and of
adjacent normal tissue was subjected to high-depth targeted MPS
using the Memorial Sloan Kettering-Integrated Mutation Profiling
of Actionable Cancer Targets (MSK-IMPACT) assay, targeting all
coding regions and select non-coding and regulatory regions of
410 genes. MSK-IMPACT sequencing yielded a median coverage of
1,065 × (range 389× –1,269 × ; Supplementary Table 2) and
revealed a median of three non-synonymous somatic mutations
per lesion (range 1–5; Supplementary Table 3). The five FELs
displayed MED12 hotspot mutations, which were clonal in all
lesions except FA2 (Figure 2; Supplementary Table 3) and
validated using Sanger sequencing and amplicon re-sequencing
(Supplementary Figure 2; Supplementary Table 4). FA2 and the
benign PT harbored an identical MED12Gly44Val mutation, whereas
FA3 and the malignant PT harbored an identical MED12Gly44Asp
mutation. The third FA displayed a distinct MED12Gly44Cys
mutation. A clonal relatedness analysis based on a previously
reported approach15 revealed that the probability of two
unrelated FELs sharing identical MED12 mutations by chance
was low (probabilities of identical Gly44Val (c.131G4T) and
Gly44Asp (c.131G4A) by chance were 0.027 and 0.006, respec-
tively, Supplementary Table 5), suggesting that the benign PT was
clonally related to FA2, whereas the malignant PT was likely
clonally related to FA3 (both Po0.05, see Materials and methods).
As the mutational repertoire of FELs of the breast differs from that
of common cancers, we performed additional Sanger sequencing
analysis of all coding regions of the FLNA gene, which is among
the genes most frequently mutated in FAs (5%) and PTs (87%) and
is not included in the list of genes analyzed by MSK-IMPACT. None
of the samples analyzed was found to harbor a somatic mutation
affecting FLNA.
Given that clonal relatedness based on the presence of a single
shared mutation, despite the statistically significant results, may
be ambiguous, we sought to define whether the proposed clonal
relatedness between FA2 and the benign PT, and between FA3
and the malignant PT would be supported by their pattern of
copy number alterations (CNAs). In fact, copy number analysis
revealed a similar pattern of CNAs in FA3 and the malignant PT,
including losses of 4p, 9q, 16p, 16q, and 19p (Figure 2c;
Supplementary Figure 3). In addition, FA3 and the malignant PT
shared three non-telomeric and non-centromeric DNA break-
points. DNA breakpoints have been shown to provide genetic
information that is useful to define the clonal relationship
between tumor samples.16 The partial identity score was
calculated based on these DNA breakpoints, as previously
described by Bollet et al.,16 for the comparisons between FA3
and the malignant PT as well as between 22 unrelated previously
described PTs6 (Supplementary Methods). The upper limit of the
95% confidence interval of the comparisons between FAs and PTs
from other patients was employed as a cutoff to infer whether two
tumors were clonally related. This revealed a partial identity score
between FA3 and the malignant PT of 0.1227, above the 0.0328
cutoff determined from the analysis of the samples included in
this study and 22 unrelated PTs (median 0.007). Taken together,
these findings support the clonal relatedness between FA3 and
the malignant PT. On the other hand, CNA analysis was non-
informative to infer clonal relatedness between FA2 and the
benign PT, given that the benign PT displayed a flat profile with
minimal CNAs (Figure 2c; Supplementary Figure 3).
Presumed pathogenic somatic mutations affecting
FGFR2Ser252Trp, KDM6AVal1207Gly, and KMT2DGln4347fs were only
found in FA2, whereas a clonal TERT promoter − 124 C4T hotspot
mutation and two distinct mutations in SETD2 were found
exclusively in the malignant PT (Figure 2a; Supplementary
Figure 1; Supplementary Table 3), one of which was subclonal.
Additional subclonal mutations were detected in the FELs
analyzed (Figure 2a; Supplementary Table 3), including a subclonal
CCND2 mutation, which was present in FA3 but absent in its
clonaly related malignant PT. These findings provide evidence to
suggest that FELs may display intratumor genetic heterogeneity.
DISCUSSION
FAs and PTs share histologic similarities, however, their diagnoses
carry fundamentally distinct clinical implications. Although FAs are
benign and do not necessarily require surgical excision, PTs
mandate surgical excision with clear margins and can display
malignant behavior. Despite their distinctive natural history,
progression from FAs to PTs has been previously
hypothesized.9,13,14,17,18 Observational studies have also reported
on the development of malignant PTs in patients with a previous
history of FAs18 and the presence of FA-like areas in PTs,9 and
studies based on loss of heterozygosity and human androgen
receptor assays have suggested clonal relatedness between
synchronous and metachronous FAs and PTs.13,14 Interestingly,
patients with previous history of FAs have been shown to display
better outcomes than those with de novo malignant PTs (i.e.,
without previous history of FA).18
Recent data demonstrating similar mutational profiles in both
FAs and PTs with frequent co-occurrence of MED12 and RARA
mutations indirectly support the hypothesis that FAs and PTs may
be clonally related. Upon analysis of five cases of concurrent or
longitudinal FAs and PTs, Tan et al.9 found shared mutations in
two cases, suggesting clonal relatedness. No formal clonality
analysis was performed and potential drivers of progression to PTs
were not identified.9 Here we provide additional molecular
evidence that PTs (including a malignant PT) may originate from
FAs based on the presence of identical somatic MED12 mutations
and similar pattern of CNAs and breakpoints. Our sequencing
analysis also revealed that only the malignant PT harbored a TERT
promoter mutation. We have recently described that TERT
promoter hotspot mutations are exclusively found in PTs, and
that their frequency increases with histologic grade;6 consistent
with these observations, a TERT promoter hotspot mutation was
solely found in the malignant PT and not in its clonally related FA.
Hence, our findings reported here and in Piscuoglio et al.6 are
consistent with the notion that TERT alterations may have a role in
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the progression to a malignant phenotype within FELs. Given that
TERT promoter hotspot mutations (i.e., − 124C4T and − 146C4T)
and TERT gene amplifications have been shown to result in
increased levels of telomerase expression and, potentially, activity
in somatic cells,19 allowing them to bypass the Hayflick limit
(i.e., telomeric crisis) and to undergo a higher number of cell
Figure 1. Representative micrographs of the ipsilateral synchronous mammary fibroepithelial lesions evaluated in this study. Representative
micrographs of three fibroadenomas (FAs) (a–c), one benign phyllodes tumor (PT) (d), and one malignant PT (e). Two FAs (a,b) displayed a
predominant pericanalicular pattern and a stromal component with usual cellularity, and no atypia or mitoses. The third FA had an
intracanalicular growth pattern and hyalinized stroma (c). The benign and malignant PTs were characterized by leaf-like architecture (d,e). The
benign PT showed moderate stromal cellularity, no significant nuclear pleomorphism, and inconspicuous mitotic activity (0 mitoses per 10
high-power fields (HPFs) (d); Supplementary Table 1), whereas the malignant PT displayed stromal expansion with marked hypercellularity (e),
moderate nuclear atypia, and mitotic activity (10 mitoses per 10 HPFs (f); Supplementary Table 1). The epithelium did not show atypia nor did
it show significant proliferation in all lesions.
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divisions, we posit that these alterations may allow for the
mesenchymal cells of PTs to proliferate and acquire further
mutations and/or CNAs, which may ultimately result in
a more aggressive form of disease. Further studies are warranted
to define the mechanistic basis of the progression from FAs to PTs
and the role of TERT somatic genetic alterations in FELs of the
breast.
The FELs studied here were anatomically separated
(Supplementary Material), although some were found to be
clonally related. A field effect is one plausible explanation for
the clonal relatedness between FA2 and the benign PT, and
between FA3 and the malignant PT. According to this theory, a
single progenitor clone expands to populate widespread areas of
an organ and may give rise to multifocal anatomically separated
lesions after acquisition of independent genetic events. Therefore,
it is possible that specialized mammary stromal cells (e.g., the
likeliest cell of origin of FELs) may acquire MED12 mutations,
populate large areas of the breast, and subsequently give rise to
distinct FELs. In fact, although FA3 and the malignant PT
shared an identical MED12 mutation and multiple DNA break-
points, they harbored private genetic alterations, including a
CCND2 somatic mutation in FA3 and somatic mutations affecting
SETD2 and the promoter of TERT in the malignant PT. These
findings are consistent with the hypothesis that these two lesions
Figure 2. Targeted capture massively parallel sequencing (MPS) analysis of five synchronously diagnosed fibroepithelial lesions. (a) Schematic
illustration of the anatomical location of the five synchronously diagnosed fibroepithelial tumors in the right breast of a 37-year-old woman
(top panel) and the results of the targeted capture MPS analysis (bottom panel). Tumor cell fractions (TCFs) were based on an integrative
analysis of mutant allele fractions, tumor cell content, ploidy, and local copy number using ABSOLUTE,20 and reported for the non-
synonymous and promoter somatic mutations identified in a given lesion. TCFs are color-coded according to the legend. Clonal mutations are
highlighted in orange boxes. In samples harboring a given mutation, the number of mutant alleles (numerator) detected is specified in its
respective text box, over the depth of coverage for that specific locus (denominator). PT, phyllodes tumor. (b) Heatmap illustrates the
repertoire of copy number alterations as defined by targeted capture MPS. Samples are represented as columns and chromosomes are
represented along the y axis, with dark gray lines demarcating the chromosomes and the light gray dotted lines representing centromeres.
Absolute copy number was defined by ABSOLUTE20 and are color-coded according to the legend to the right of the heatmap.
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shared a common ancestor, but diverged early in their tumor
evolution.
This study has several limitations. First, we have studied samples
from a single patient. Despite this limitation, the clonal relatedness
analysis performed here and the results reported by Tan et al.9 are
in agreement in that FAs may be clonally related to PTs, and that
distinct FELs in the same patient may harbor distinct MED12
mutations. Second, MSK-IMPACT yielded a limited number of
somatic mutations in FAs, thus whole-exome or whole-genome
sequencing analysis could theoretically have provided more
conclusive results. It should be noted, however, that the number
of genes mutated beyond MED12 in FAs has been shown to be
limited,9 rendering the additional information provided by whole-
exome sequencing likely non-informative for clonality analysis. As
the samples included in this study were formalin-fixed paraffin-
embedded, whole-genome sequencing could not be performed.
Despite these limitations, our data support the contention that a
subset of FAs is clonal, neoplastic, and may constitute the
substrate from which some PTs arise. Although our data support
the contention that a subset of FAs are precursors of benign, as
well as malignant PTs, we do not advocate a change in the current
treatment of FAs, given that the likelihood of and time for the
progression from FAs to PTs has yet to be fully defined. On the
basis of the prevalence of FAs, it is plausible that the progression
rate of FAs to PTs is likely to be sufficiently low to allow FAs to be
followed rather than surgically excised, unless other clinicopatho-
logical variables indicate excision.
MATERIALS AND METHODS
Case
The diagnostic slides and formalin-fixed paraffin-embedded tissue blocks
of five synchronous ipsilateral mammary FELs from a 37-year-old female
patient were retrieved from the Department of Pathology of Memorial
Sloan Kettering Cancer Center (MSKCC). The samples were anonymized
before analysis, the study was approved by the MSKCC Institutional Review
Board (WA047-14 and WA0102-13), and informed consent was obtained.
All histologic sections of the FELs were independently reviewed by four
expert breast pathologists (FCG, MPM, EB, and JSR-F) and classified
according to the latest World Health Organization criteria.1 Microdissection
and nucleic acid extraction were performed as previously described6
(Supplementary Methods).
Targeted capture MPS
MPS analyses of the DNA extracted from the five FELs and the matched
normal were profiled using the MSK-IMPACT sequencing assay using
validated protocols6,15 (Supplementary Methods).
The tumor cell fraction of each mutation, in a way akin to the cancer cell
fraction, and the absolute copy number were inferred using ABSOLUTE
(v1.0.6)20 as previously described6,21 (Supplementary Methods).
FLNA gene Sanger sequencing
Sanger sequencing of all coding regions of FLNA was performed in all five
samples, as previously described.6 Details of the sequencing analysis and
primer sequences are available in the Supplementary Methods and
Supplementary Table 6.
Validation of mutations identified by MPS using Sanger
sequencing and amplicon resequencing
Somatic mutations in MED12 (exon 2) and TERT promoter were validated
using Sanger sequencing and amplicon resequencing, as previously
described.6,21 Details of the sequencing analysis and primer sequences
are available in the Supplementary Methods and Supplementary Table 5.
Clonal relatedness of synchronously diagnosed FELs
To determine whether the five FELs were clonally related, we used the
previously published frequency of MED12 exon 2 mutations in 98 unrelated
FAs3 and 79 unrelated PTs9 to determine the probability of two unrelated
FELs sharing identical MED12 exon 2 mutations,3,9 adopting a previously
described approach.15 On the basis of these datasets, the Gly44Val
(c.131G4T) and Gly44Asp (c.131G4A) mutations were found in 8%
(14/177) and 16% (29/177) of FAs and PTs, respectively, and the probabilities
of two unrelated samples sharing identical Gly44Val (c.131G4T) and
Gly44Asp (c.131G4A) were 0.006 and 0.027, respectively (Supplementary
Table 5). Given the reported prevalence of MED12 mutations varies across
the various publications, we further applied the same approach to a data set
from our previous publications consisting of 100 unrelated FAs6 and 76
unrelated PTs,6 with 7% (13/176) and 21% (37/176) harboring the Gly44Val
(c.131G4T) and Gly44Asp (c.131G4A) mutations, respectively, with the
probabilities of two unrelated samples sharing these identical mutations as
0.006 and 0.044, respectively (Supplementary Table 5).
Availability of data and materials
Sequencing data have been deposited to the National Center for
Biotechnology Information Sequence Read Archive under the accession
SRP062618.
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